Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 31, 2015 7:30 AM ET


Company Overview of Provectus Biopharmaceuticals, Inc.

Company Overview

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line includes PV-10, which is in Phase III study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. The company is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and sev...

7327 Oak Ridge Highway

Suite A

Knoxville, TN 37931

United States

Founded in 2002

4 Employees





Key Executives for Provectus Biopharmaceuticals, Inc.

Chairman, Chief Executive Officer, Chief Executive Officer of Xantech and Director of Xantech
Age: 63
Total Annual Compensation: $500.0K
President, Director, President of Xantech and Director of Xantech
Age: 57
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corporate Treasurer and Secretary
Age: 56
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice President
Age: 52
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

Provectus Biopharmaceuticals, Inc. Key Developments

Provectus Biopharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Provectus Biopharmaceuticals, Inc. announced that they will report Q2, 2015 results at 1:00 PM, GMT Standard Time on Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Provectus Biopharmaceuticals Mulls Acquisitions

Provectus Biopharmaceuticals, Inc. (AMEX:PVCT) filed a shelf registration in the amount of $100 million and intends to use the proceeds for the expansion of our business through internal growth or acquisitions.

Similar Private Companies By Industry

Company Name Region
Aptalis Pharma Inc. United States
Nitric Bio, Inc. United States United States
Symmetry Corporation United States
Solstice Holdings Inc. United States

Recent Private Companies Transactions

Private Placement
October 15, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Provectus Biopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at